Compare Wells Fargo & Co (WFC) vs State Street SPDR S&P Biotech ETF (XBI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Wells Fargo & Co vs State Street SPDR S&P Biotech ETF — how do they compare? Wells Fargo & Co trades at $88.25 (market cap $264.66B), while State Street SPDR S&P Biotech ETF trades at $159. The key difference: Wells Fargo & Co pays a 2.29% dividend while State Street SPDR S&P Biotech ETF pays none, and State Street SPDR S&P Biotech ETF is trading nearer its 52-week high, Wells Fargo & Co nearer its low. Which is the better fit depends on your goals.
| WFC | XBI | |
|---|---|---|
Market Cap | $264.66B | — |
Sector | Financials | Broad Market / Factor |
52-Week High | $96.40 | $164.28 |
52-Week Low | $73.42 | $86.92 |
Dividend Yield | 2.29% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Wells Fargo (WFC) trades at $87.55, up 0.34% today, with a bullish technical signal from moving averages. The stock shows strong fundamentals, including a P/E of 12.72, net income margin of 25.97%, and ROE of 13.13%. Recent earnings beat expectations in Q2 2026, and the company is expanding digital services like tokenized deposits. Analyst consensus is mixed but leans positive, with a price target of $97.64.
The outlook for WFC is favorable, driven by earnings growth and strategic innovations, though risks include volatile cash flows and economic sensitivity. Upside potential exists if the company meets future earnings and maintains profitability, but investors should monitor execution and macroeconomic factors.
XBI trades at $159.15, up 0.71% with a bullish technical signal from moving averages. The biotech ETF shows strong momentum with a 17% monthly gain, driven by positive clinical data and M&A activity. Analyst coverage remains limited with a single hold rating, while institutional interest grows with recent $793,000 investment from Bay Colony Advisors.
Outlook remains positive given biotech sector resurgence, though elevated RSI suggests near-term overbought conditions. Key risks include sector volatility and regulatory uncertainty, but AI-driven drug discovery and strong pipeline developments provide growth catalysts for patient investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Wells Fargo & Co
Wells Fargo is one of the largest banks in the United States, with approximately $1.9 trillion in balance sheet assets. The company is split into four primary segments: consumer banking, commercial banking, corporate and investment banking, and wealth and investment management. It is almost entirely focused on the U.S.
Read more on WFC →About State Street SPDR S&P Biotech ETF
XBI is an equal-weighted ETF that tracks the U.S. biotechnology segment. It provides diversified exposure to small, mid, and large-cap biotech firms involved in drug discovery and medical research, such as Moderna and Exact Sciences.
Read more on XBI →
